ArticleTranslational oncology2025
ALAD as a prognostic biomarker regulates metabolism and immune responses in renal cell carcinoma through multi-omics analysis.
Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Reading the tumour at single-cell resolution: Original research in the Precision Therapeutics special issue.Translational oncology · 2026Article
- Comprehensive bioinformatics and experimental analysis of PPOX reveals its carcinogenic effect in clear cell renal cell carcinoma.Translational andrology and urology · 2026Article
- Integrative multi-omics profiling for early diagnosis, stratification and personalized management of chronic kidney disease: a new paradigm.Clinical and experimental medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal cell carcinoma (RCC) is a common malignant tumor with metabolic reprogramming and immune evasion features. δ-Aminolevulinic acid dehydratase (ALAD), a key enzyme in heme biosynthesis, has been implicated in cancer progression and treatment outcomes, but its role in RCC remains unclear.
methodsThis study integrated multi-omics datasets from TCGA, CPTAC, and GEO to analyze ALAD's expression, prognostic value, and functional implications in RCC.
resultsThe results showed that ALAD expression is significantly downregulated in RCC tissues at both transcriptomic and proteomic levels, with low expression associated with advanced tumor stages, poor prognosis, and altered metabolic pathways. Functional enrichment and metabolic signature analyses revealed ALAD's association with metabolic processes and immune cell infiltration, particularly impacting CD8+ T cell-mediated immunity. Furthermore, ALAD expression correlated with sensitivity to specific anticancer drugs, suggesting potential therapeutic implications that required functional confirmation.
conclusionOverall, this study suggestes that ALAD is a promising prognostic biomarker and therapeutic target in RCC, highlighting its role in modulating the tumor immune microenvironment and metabolic landscape. These findings highlight an association between ALAD and RCC progression, though experimental validation is needed to confirm causality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.